Cemiplimab-rwlc
Cemiplimab-rwlc
Cemiplimab-rwlc (pronounced as sem'i pli mab), also known by its brand name Libtayo, is a type of monoclonal antibody used in the treatment of certain types of cancer. It is specifically used for the treatment of cutaneous squamous cell carcinoma (CSCC) that is locally advanced or metastatic and cannot be cured by surgery or radiation.
Etymology
The name Cemiplimab-rwlc is derived from the International Nonproprietary Names (INN), where 'Ce' refers to cancer treatment, 'i' indicates it is an immune system modulator, 'mab' signifies it is a monoclonal antibody, and 'r' is for human, 'w' for Serine, 'l' for Lysine, and 'c' for Cysteine in the complementarity-determining region (CDR).
Mechanism of Action
Cemiplimab-rwlc works by binding to the PD-1 receptor and blocking its interaction with PD-L1 and PD-L2. This releases PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Related Terms
- Monoclonal antibody
- Cancer
- Cutaneous squamous cell carcinoma
- Immune system
- Programmed cell death protein 1
- PD-L1
- PD-L2
External links
- Medical encyclopedia article on Cemiplimab-rwlc
- Wikipedia's article - Cemiplimab-rwlc
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski